Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. BB Biotech AG
  6. News
  7. Summary
    BION   CH0038389992


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BB Biotech AG publishes its interim report

10/22/2021 | 05:17am EST

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Interim Report BB Biotech AG publishes its interim report 22-Oct-2021 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.


Ad hoc announcement pursuant to Art. 53 of the SIX Listing Rules

October 22, 2021

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at September 30, 2021, which covers the results of its business activities for the first nine months of 2021.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended September 30, 2021 amounted to CHF 141 mn (profit of CHF 26 mn in the same period 2020). In the third quarter a loss of CHF 208 mn (loss of CHF 395 mn in the corresponding period of the previous year) was incurred. For an investment company, the reported profit reflects the performance of the stocks that it holds in its portfolio.

BB Biotech AG's interim report as at September 30, 2021 is available under report.bbbiotech.ch/Q321 or www.bbbiotech.com.

For further information: Media Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, Tel. +41 44 267 67 00 Tanja Chicherio, tch@bellevue.ch www.bbbiotech.com

Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech AG is one of the leading investors in this sector. BB Biotech AG builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.


22-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de


Language:     English 
Company:      BB BIOTECH AG 
              Schwertstrasse 6 
              8200 Schaffhausen 
Phone:        +41 52 624 08 45 
E-mail:       info@bbbiotech.com 
Internet:     www.bbbiotech.ch 
ISIN:         CH0038389992 
WKN:          A0NFN3 
Listed:       Regulated Market in Frankfurt (Prime Standard); Mailand, SIX 
EQS News ID:  1242635 
End of Announcement  DGAP News Service 

1242635 22-Oct-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1242635&application_name=news

(END) Dow Jones Newswires

October 22, 2021 05:16 ET (09:16 GMT)

All news about BB BIOTECH AG
10/22BB Biotech AG Reports Earnings Results for the Third Quarter and Nine Months Ended Sept..
10/22BB BIOTECH : Q3 Net Loss Shrinks
10/22BB BIOTECH : increases positions in oncology and CNS
10/22BB BIOTECH : publishes its interim report
10/22BB BIOTECH : Gains realized following COVID-19 vaccine booster update enable increases in ..
07/23Bb Biotech Ag Reports Earnings Results for the Second Quarter Ended June 30, 2021
07/23BB BIOTECH : Posts Lower H1 Profit, Operating Income
07/23BB BIOTECH : Interim report as at June 30, 2021
07/23BB BIOTECH : publishes its interim report
07/23BB BIOTECH : Solid second quarter for the biotech industry - BB Biotech raised its allocat..
More news
Analyst Recommendations on BB BIOTECH AG
More recommendations
Sales 2021 -87,5 M -95,0 M -95,0 M
Net income 2021 439 M 477 M 477 M
Net Debt 2021 23,5 M 25,5 M 25,5 M
P/E ratio 2021 7,63x
Yield 2021 5,18%
Capitalization 4 299 M 4 663 M 4 667 M
EV / Sales 2021 -49,4x
EV / Sales 2022 -
Nbr of Employees 10
Free-Float 98,1%
Duration : Period :
BB Biotech AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 77,60 CHF
Average target price 97,00 CHF
Spread / Average Target 25,0%
EPS Revisions
Managers and Directors
Michael Hutter Head-Finance & Compliance
Erich Hunziker Chairman-Supervisory Board
Daniel Koller Head-Investment Management
Clive A. Meanwell Vice Chairman-Supervisory Board
Thomas von Planta Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BB BIOTECH AG4.32%4 625
MODERNA, INC.170.27%114 479
LONZA GROUP AG24.16%58 572
SEAGEN INC.-16.39%26 777
CELLTRION, INC.-42.20%23 611